Solventum Corporation

SOLV Healthcare Medical Instruments & Supplies

Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.

85.81 2.05 −2.33%
Market cap
$15.0B
P/E
10.4×
Fwd P/E
39.0×
Dividend yield
—
F-score
5/9
Altman Z
2.22
Beneish M
−2.07
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
6 5 5 —

+8 more TTM periods

ROE
33.96% 34.79% 38.86% 37.27%
ROA
9.78% 10.01% 10.82% 10.61%
ROIC
13.40% 13.60% 14.81% 16.15%
Return on Tangible Assets
87.28% 80.45% 75.94% 54.33%
Average Days of Receivables
62.90 52.13 51.91 51.09
Free Cash Flow per Share
(0.68) (1.17) (0.06) 0.29
Free Cash Flow
(118.00) (203.00) (10.00) 50.00
Other line items

Show all line items

Columns are period end dates